AI Terminal
NFL Biosciences
Report Publication Announcement • Mar 5, 2025
1553_iss_2025-03-05_e5c5bc5c-853e-4ab2-8853-64386d9ee7c4.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
Press release
NFL Biosciences publishes its 2025 financial agenda
Montpellier, France, March 5 th, 2025, 5:45 p.m. CET – NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALFNL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, presents its financial agenda for 2025.
| Events | Dates * |
|---|---|
| 2024 annual results | th 2025 April 11 |
| Annual General Meeting (Montpellier) | June 25th 2025 |
| 2025 half-year results | th 2025 October 24 |
*Press releases will be published after the close of the stock market
The calendar is provided for information purposes only and may be subject to modification.
About NFL Biosciences: www.nflbiosciences.com
NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.
The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL).
Contacts:
Investors relations / Media relations Mathilde Bohin / Arthur Rouillé Tel.: +33 (0)1 44 71 94 94 E-mail: [email protected]
NewCap NFL Biosciences
Bruno Lafont Tél.: +33 (0)4 11 93 76 67 E-mail: [email protected]